A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis
ACP-204-008
Phase 3 other active
Quick answer
A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis for Alzheimer's Disease Psychosis is a Phase 3 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Alzheimer's Disease Psychosis
- Phase
- Phase 3
- Modality
- other
- Status
- active